Lite Strategy Inc (LITS)

• Market cap: $39.3M
• 1 day: -5.26%
• 5 days: -1.82%
• 1 month: -18.18%
• 3 months: -42.86%
• 6 months: -79.07%
• Year to date: -29.87%
• 1 year: -58.3%
• 5 years: -98.59%
• 10 years: -95.34%
• Sector: Healthcare
• Industry: Biotechnology

About: Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.

Employees: 4